CD29 (Integrin beta 1) Monoclonal Antibody (TS2/16), NovaFluor™ Blue 660-120S, eBioscience™, Invitrogen™

ITGB1 (Integrin Subunit Beta 1, beta1 integrin subunit, GPIIa, CD29) is a 110 kDa cell surface glycoprotein that is widely expressed by a variety of cells including all leucocytes. ITGB1 forms non-covalently linked heterodimers with at least 6 different alpha chains (alpha1-alpha6, CDa-f) determining the binding properties of beta1 (VLA) integrins. ITGB1 is a cell adhesion molecule appearing on platelets, as the common Beta subunit of the very late activation antigen (VLA), and as a component of various protein complexes binding to extracellular matrix proteins. Decreased expression of ITGB1 correlates with acquiring multidrug resistance of tumor cells in the presence of anti-tumor drug. ITGB1 is up-regulated in leukocytes during emigration and extravascular migration and appear to be critically involved in regulating the immune cell trafficking from blood to tissue. Further, ITGB1 also regulates tissue damage and disease symptoms related to inflammatory bowel disease. Through an ITGB1-dependent mechanism, fibronectin and type I collagen enhance cytokine secretion of human airway smooth muscle in response to IL-1beta. More than 8 beta subunits with numerous splice variant isoforms have been identified in mammals. There are two major forms of integrin beta1: beta1A and beta1D, which differ in 13 amino acids. The distribution pattern in adult tissues for integrin beta types are mutually exclusive. Beta1A is present in all tissues, except cardiac and skeletal muscle which express the beta1D variant.